Disease Domain | Count |
---|---|
Neoplasms | 8 |
Endocrinology and Metabolic Disease | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 7 |
Synthetic peptide | 4 |
Diagnostic radiopharmaceuticals | 2 |
Radiolabeled antibody | 1 |
Contrast agent | 1 |
Target |
Mechanism PDK4 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism RANK inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism LAG3 inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date24 Mar 2025 |
Sponsor / Collaborator |
Start Date05 Aug 2024 |
Sponsor / Collaborator |
Start Date04 Mar 2019 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
PPAR δ agonist (Daegu-Gyeongbuk Medical Innovation Foundation) ( PPARδ ) | Inflammation More | Preclinical |
64Cu-PCB-TE2A-Tz ( HNRNPA2B1 ) | Triple Negative Breast Cancer More | Preclinical |
Gd-Ga(Kyungpook National University) ( LY96 ) | Inflammation More | Preclinical |
KARI-201 ( GHSR x SMPD1 ) | Alzheimer Disease More | Preclinical |
KP-A038 ( RANK ) | Osteoporosis More | Preclinical |